Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lowered its holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 95.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,800 shares of the company's stock after selling 316,400 shares during the period. Two Sigma Advisers LP's holdings in Cardiff Oncology were worth $64,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRDF. Bank of New York Mellon Corp increased its holdings in Cardiff Oncology by 68.7% in the 4th quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock valued at $1,253,000 after purchasing an additional 117,514 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of Cardiff Oncology by 73.7% in the fourth quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock worth $2,546,000 after buying an additional 248,850 shares during the period. Laurion Capital Management LP acquired a new stake in shares of Cardiff Oncology in the fourth quarter valued at about $2,504,000. American Century Companies Inc. raised its holdings in shares of Cardiff Oncology by 12.8% during the 4th quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after buying an additional 6,140 shares during the period. Finally, Northern Trust Corp lifted its position in Cardiff Oncology by 8.9% during the 4th quarter. Northern Trust Corp now owns 337,092 shares of the company's stock worth $1,463,000 after acquiring an additional 27,489 shares in the last quarter. Hedge funds and other institutional investors own 16.29% of the company's stock.

Cardiff Oncology Stock Performance

Shares of CRDF stock traded down $0.08 during trading hours on Thursday, hitting $3.79. 866,300 shares of the company were exchanged, compared to its average volume of 1,165,043. The business's 50-day simple moving average is $2.96 and its two-hundred day simple moving average is $3.50. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $5.64. The stock has a market capitalization of $252.13 million, a price-to-earnings ratio of -4.03 and a beta of 1.61.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative net margin of 6,238.17% and a negative return on equity of 73.97%. As a group, analysts anticipate that Cardiff Oncology, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price objective on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, May 9th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.